secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAMED PHARMACEUTICALS INC. (ORMP)
CIK:        0001176309
Form:       8-K
Filed at:   2024-09-26T23:59:59+00:00
Accession:  0001213900-24-082237
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oramed signs $11.5M CRO agreement for Phase 3 trial of ORMD-0801 in type 2 diabetes
--------------------------------------------------------------------------------

- Oramed Ltd. subsidiary retained InClin as CRO for planned Phase 3 trial of oral insulin candidate ORMD-0801.
- Trial to assess safety/efficacy in approximately 300 type 2 diabetes patients under US IND.
- Total consideration up to ~$11.5 million, paid monthly based on hours performed over engagement.
- Sponsor can terminate with or without cause on 30 days' notice; standard cure period for breach.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1176309/000121390024082237/0001213900-24-082237-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1176309/000121390024082237/ea0215648-8k_oramed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-082237

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer